Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,514 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ACTION Clear all
Recruiting Phase 4 Interventional

Secondhand Tobacco Smoke and Cardiovascular Disease

NCT04715568
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

NCT02342691
View directory record Official record
Conditions
Gingival Inflammation
Interventions
BLXA4, Placebo oral rinse
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Auriculotherapy for Smoking Cessation: Pilot

NCT01189110
View directory record Official record
Conditions
Smoking Cessation
Interventions
Auriculotherapy using TENS unit Stim Flex 400A
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 2, 2026, 6:22 AM EDT
Not listed Phase 2 Interventional

Statins and Breast Cancer Biomarkers

NCT00914017
View directory record Official record
Conditions
Breast Cancer
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
San Francisco, California • Newark, Delaware • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Phase 4 Interventional Results available

Mechanism of Action Study for Psoriasis

NCT00932113
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Adalimumab (Humira)
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 2, 2026, 6:22 AM EDT
Terminated Phase 1 Interventional

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

NCT01081808
View directory record Official record
Conditions
Neoplasms, Tumors, Solid Tumors, Metastatic Cancer
Interventions
EGFRBi-armed autologous activated T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 2, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional Results available

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

NCT00365274
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

NCT01081223
View directory record Official record
Conditions
Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
Interventions
Cancer vaccine plus immune adjuvant
Biological
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 2, 2026, 6:22 AM EDT
Active, not recruiting Phase 1 Interventional

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217
View directory record Official record
Conditions
Metastatic Neuroendocrine Prostate Cancer
Interventions
[68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Not applicable Interventional Results available

Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

NCT00934843
View directory record Official record
Conditions
Congenital Heart Disease, Disorder of Fetus or Newborn
Interventions
methylprednisolone (IVMP), methylprednisolone (two doses IVMP)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Up to 30 Days
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Dialysis CHW Pilot

NCT05998850
View directory record Official record
Conditions
Chronic Kidney Diseases, RENAL INSUFFICIENCY, CHRONIC
Interventions
Community Health Worker Support with Resources
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

NCT01137474
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo-matching dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
164
States / cities
Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 2, 2026, 6:22 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

NCT01605318
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions
Labetuzumab Govitecan (LG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 2, 2026, 6:22 AM EDT
Recruiting Phase 3 Interventional

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

NCT05699174
View directory record Official record
Conditions
Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions
Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 6:22 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090
View directory record Official record
Conditions
Healthy Participants
Interventions
Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

Promoting Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) Through New Technology and Health Coaching

NCT01217710
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Physical Activity
Interventions
Activity monitor/smartphone health coaching
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

NCT00836485
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 2, 2026, 6:22 AM EDT
Active, not recruiting Early Phase 1 Interventional

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

NCT03910452
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Busulfan, Alemtuzumab, Cyclophosphamide, Sirolimus, Total Body Irradiation, Allogeneic peripheral blood stem cell
Drug · Radiation · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Not applicable Interventional Results available

Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients

NCT00133978
View directory record Official record
Conditions
Critical Illness, Sepsis, Multiple Organ Failure
Interventions
Glutamine, Antioxidants, Glutamine + Antioxidants, Placebo
Other
Lead sponsor
Daren K. Heyland
Other
Eligibility
18 Years and older
Enrollment
1,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Aurora, Colorado • Louisville, Kentucky • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 2, 2026, 6:22 AM EDT
Completed No phase listed Observational

CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)

NCT02184117
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Adenosine, Contrast Media, Resting conditions
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Palo Alto, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 2, 2026, 6:22 AM EDT
Recruiting Phase 1 Interventional

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

NCT04777994
View directory record Official record
Conditions
Advanced Solid Tumor Cancer
Interventions
ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
Drug
Lead sponsor
Calico Life Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

NCT01827137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Galinpepimut-S, GM-CSF, Montanide, lenalidomide, bortezomib
Biological · Other · Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 6:22 AM EDT
Not listed Phase 2 Interventional

Hormone Replacement Therapy and Insulin Action: A Double-Blind, Parallel, Placebo-Controlled Hormone Intervention Study in Postmenopausal Women

NCT00005769
View directory record Official record
Conditions
Menopause
Interventions
Hormone Replacement Therapy
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
45 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Physiological Mechanisms of Therapeutic Horseback Riding Intervention Effects in a Psychiatric Population of ASD Youth

NCT04606966
View directory record Official record
Conditions
Autism Spectrum Disorder, Mental Disorders
Interventions
Therapeutic Horseback Riding, Barn Activity, Hybrid
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 17 Years
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Aurora, Colorado • Portland, Maine
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 2, 2026, 6:22 AM EDT